MLN0128_101 Safety, Tolerability, PK and PD MAD Study in IPF patients

• Research type

  Research Study

• Full title

  A Phase 1b Multiple Ascending Dose Study to Investigate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MLN0128 Following 7 days Repeat Oral Doses in Subjects with Idiopathic Pulmonary Fibrosis

• IRAS ID

  148150

• Contact name

  Toby Maher

• Contact email

  t.maher@rbht.nhs.uk.

• Sponsor organisation

  Takeda Development Centre Europe Ltd

• Eudract number

  2013-003524-36

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  14/LO/0351

• Date of REC Opinion

  14 May 2014

• REC opinion

  Further Information Favourable Opinion